Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.

The Tohoku journal of experimental medicine - 1 Apr 2007

Fukumoto Yoshihiro, Tawara Shunsuke, Shimokawa Hiroaki

Abstract excerpt

Pulmonary arterial hypertension (PAH) is a disease with poor prognosis characterized by progressive elevation of pulmonary arterial pressure and vascular resistance due to pulmonary artery hyperconstriction and remodeling. However, the precise mechanism of PAH still remains to be elucidated. Although anticoagulant agents, vasodilators (e.g., prostaglandins, sildenafil, and bosentan), and lung transplantation are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PAH gene
Share to Hypertension, Pulmonary
Share to Intracellular Signaling Peptides and Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to rho-Associated Kinases

Share to Vasodilator Agents

Source

Identifiers

PMID: 17409670
DOI: 10.1620/tjem.211.309

Genes

PAH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors.PMID 17409670Read ↗

RhoGTPase in Vascular DiseaseSemantic proximity Read ↗

Anticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial HypertensionSemantic proximity Read ↗

Management of Pulmonary Arterial Hypertension. Current Strategies and Future ProspectsSemantic proximity Read ↗

Developments in therapeutics for pulmonary arterial hypertension.Semantic proximity Read ↗

Involvement of Rho GTPases and their regulators in the pathogenesis of hypertensionSemantic proximity Read ↗

PTBP1 Targets ILK to Regulate the Hypoxia-Induced Phenotypic Transformation of Pulmonary Artery Smooth Muscle Cells.Semantic proximity Read ↗

From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension.Semantic proximity Read ↗

Reconciling paradigms of abnormal pulmonary blood flow and quasi-malignant cellular alterations in pulmonary arterial hypertension.Semantic proximity Read ↗

Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertensionSemantic proximity Read ↗

Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studiesSemantic proximity Read ↗

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study.Semantic proximity Read ↗

Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.